how big is Checkpoint Trend?

As of Jun 06, Checkpoint Trends Ltd has a market capitalization of 10.00 Cr, with recent net sales of 0.50 Cr and a net profit of 0.02 Cr over the last four quarters. Shareholder's funds are 0.53 Cr, and total assets are 0.93 Cr as of Mar'24.

Market Cap: As of Jun 06, Checkpoint Trends Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 0.50 Cr. The sum of Net Profit for the same quarters is 0.02 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 0.53 Cr, while Total Assets amount to 0.93 Cr.

When is the next results date for Checkpoint Trend?

No Upcoming Board Meetings

Who are in the management team of Checkpoint Trend?

As of March 2022, the management team of Checkpoint Trend includes Abha Kapoor (CFO), Sunil Khandelwal (Managing Director), Ritu Chhatani (Company Secretary), and independent directors Sneha Thakur, Gopal Sahu, and Harish Surve, who oversee operations and compliance.

As of March 2022, the management team of Checkpoint Trend includes the following members:<BR><BR>1. Abha Kapoor - Director (Finance) & CFO<BR>2. Sneha Thakur - Independent Director<BR>3. Sunil Khandelwal - Managing Director<BR>4. Gopal Sahu - Independent Director<BR>5. Ritu Chhatani - Company Secretary & Compliance Officer<BR>6. Harish Surve - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and ensuring compliance with regulations.

What does Checkpoint Trend do?

Checkpoint Trends Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, providing trading and consulting services. As of March 2025, it reported net sales and net profit of 0 Cr, with a market cap of Rs 9 Cr.

Overview: <BR>Checkpoint Trends Ltd is engaged in the business of trading and provides various consulting services within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Checkpoint Trends Ltd was established in 1991 and was formerly known as Rubra Medicaments Ltd. The company name was changed in April 2022. The latest quarterly results reported net sales and net profit of 0 Cr for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 9 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 10.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.04 <BR>Return on Equity: 1.71% <BR>Price to Book: 9.70 <BR><BR>Contact Details: <BR>Address: 604 6th Floor Meghdoot, Mogul Lines Staff CHSL JVPD Sc Mumbai Maharashtra : 400049 <BR>Tel: 91-9167469649 <BR>Email: rubraltd@gmail.com <BR>Website: http://www.rubramed.com

Has Checkpoint Trend declared dividend?

No Dividend History Available

Who are the peers of the Checkpoint Trend?

Peers of Checkpoint Trend include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Checkpoint Trend has a 1-year return of 110.41%, outperforming its peers, while management risk varies from excellent to below average across the group.

Peers: The peers of Checkpoint Trend are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Unjha Formul., Vivanza Biosci., Cian Healthcare, Beryl Drugs, and Ortin Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is noted at Unjha Formul., Cian Healthcare, Beryl Drugs, and Ortin Global, while Below Average management risk is seen at Vivanza Biosci. and Checkpoint Trend. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, Below Average for Divi's Lab., Torrent Pharma, Unjha Formul., Cian Healthcare, Beryl Drugs, Ortin Global, and Checkpoint Trend, and Below Average for Vivanza Biosci. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma and Unjha Formul., and Below Average for Divi's Lab., Vivanza Biosci., Checkpoint Trend, Cian Healthcare, Beryl Drugs, and Ortin Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Vivanza Biosci. at -60.94%. Checkpoint Trend's own 1-year return is 110.41%, which is significantly higher than all peers. Additionally, Unjha Formul., Vivanza Biosci., Cian Healthcare, Beryl Drugs, and Ortin Global all have negative six-month returns.

What is the technical trend for Checkpoint Trend?

As of May 29, 2025, Checkpoint Trend shows a mildly bullish outlook, supported by daily moving averages and monthly KST, despite some short-term bearish signals from weekly MACD and RSI.

As of 29 May 2025, the technical trend for Checkpoint Trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the monthly KST remaining bullish. However, the weekly MACD and RSI are showing mildly bearish and bearish signals respectively, which temper the overall bullish outlook. The Bollinger Bands are also indicating mild bullishness on both weekly and monthly time frames. Overall, while there are some bearish signals in the short term, the longer-term indicators suggest a cautiously optimistic view.

Who are the top shareholders of the Checkpoint Trend?

The top shareholders of Checkpoint Trend are individual investors with 71.77% of shares, followed by Religare Finvest Ltd at 5.89%, and two foreign institutional investors holding a combined 10.85%. There are no pledged promoter holdings or mutual funds in the shareholding structure.

The top shareholders of Checkpoint Trend include individual investors, who hold a significant 71.77% of the shares. Additionally, Religare Finvest Ltd is the highest public shareholder with a stake of 5.89%. The company also has two foreign institutional investors (FIIs) holding a combined 10.85%. There are no pledged promoter holdings or mutual funds involved in the shareholding structure.

How has been the historical performance of Checkpoint Trend?

Checkpoint Trend's historical performance shows a decline in net sales from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25, with total operating income and expenditures also decreasing. However, operating profit improved from a loss in Mar'23 to a profit in Mar'25, while total assets and liabilities decreased, indicating a stagnant cash position.

Answer:<BR>The historical performance of Checkpoint Trend shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Checkpoint Trend's net sales have seen a decline from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25, with a notable drop from 1.16 Cr in Mar'23. The total operating income followed a similar trend, decreasing from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 2.03 Cr in Mar'22 to 0.44 Cr in Mar'25. Operating profit (PBDIT) showed a slight improvement, moving from a loss of 0.08 Cr in Mar'23 to a profit of 0.06 Cr in Mar'25. Profit before tax improved from a loss of 0.08 Cr in Mar'23 to a profit of 0.05 Cr in Mar'25, while profit after tax remained stable at 0.03 Cr for both Mar'24 and Mar'25. The company's total assets decreased from 0.93 Cr in Mar'24 to 0.65 Cr in Mar'25, and total liabilities also declined from 0.93 Cr to 0.65 Cr in the same period. Cash flow figures indicate no cash inflow or outflow across the years, reflecting a stagnant cash position.

Are Checkpoint Trend latest results good or bad?

Checkpoint Trends' latest results show impressive revenue growth, with net sales up 827.33% quarter-on-quarter and a return to profitability with a net profit of ₹1.32 crore. However, significant concerns arise from a drastic drop in operating margins to 1.65% and an extremely high price-to-earnings ratio of 492x, indicating potential risks for investors.

The latest results for Checkpoint Trends present a mixed picture. On one hand, the company achieved remarkable revenue growth, with net sales increasing by 827.33% quarter-on-quarter and an astonishing 217,080% year-on-year. This growth has translated into a net profit of ₹1.32 crore, marking a significant turnaround from previous losses.<BR><BR>However, the results also reveal significant concerns regarding profitability. Operating margins have plummeted from 36.00% in the previous quarter to just 1.65% in the latest quarter. This drastic compression raises questions about the sustainability of the company's growth, as it suggests that the company may be prioritizing volume over profitability.<BR><BR>Additionally, despite the impressive revenue figures, the company's overall financial health is precarious, with a low return on equity and a high valuation relative to its earnings. The stock trades at a price-to-earnings ratio of 492x, which is extraordinarily high compared to industry averages.<BR><BR>In summary, while Checkpoint Trends has demonstrated explosive growth in sales and a return to profitability, the sharp decline in margins and extreme valuation multiples indicate potential risks that investors should carefully consider.

Should I buy, sell or hold Checkpoint Trend?

Is Checkpoint Trend overvalued or undervalued?

As of November 13, 2025, Checkpoint Trend is considered undervalued with a favorable valuation grade shift, featuring a PE ratio of 30.19 and a year-to-date return of 512.18%, significantly outperforming its peers and the Sensex.

As of 13 November 2025, Checkpoint Trend's valuation grade has moved from very expensive to attractive, indicating a significant shift in its market perception. The company is currently assessed as undervalued, particularly in light of its impressive financial metrics. Key ratios include a PE ratio of 30.19, an EV to EBITDA ratio of 22.62, and a PEG ratio of 0.04, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Checkpoint Trend's valuation appears favorable. For instance, Sun Pharma has a PE ratio of 36.15 and an EV to EBITDA of 23.85, while Cipla, which is also rated attractive, has a PE of 22.65. Notably, Checkpoint Trend's return performance has significantly outpaced the Sensex, with a year-to-date return of 512.18% compared to the Sensex's 8.11%, reinforcing the notion that the stock is undervalued relative to its growth trajectory.

Which are the latest news on Checkpoint Trend?

Why is Checkpoint Trend falling/rising?

As of 14-Dec, Checkpoint Trends Ltd's stock price is declining, currently at 107.29, down 1.99% and part of a broader trend with a total drop of 5.86% over three days. Investor interest has waned significantly, with delivery volume down 92.63% from the 5-day average, despite strong long-term performance.

As of 14-Dec, Checkpoint Trends Ltd's stock price is falling, currently at 107.29, reflecting a decrease of 2.18 or 1.99%. This decline is part of a broader trend, as the stock has been losing value for the last three days, resulting in a total drop of 5.86% during this period. Additionally, the stock has underperformed its sector by 2.04% today.<BR><BR>Investor participation has also decreased significantly, with delivery volume dropping by 92.63% compared to the 5-day average, indicating reduced interest from investors. Despite the stock's impressive long-term performance, including a year-to-date increase of 722.15% and a 1-year return of 615.27%, the recent short-term trends suggest a lack of momentum.<BR><BR>Moreover, while the stock is trading above its 20-day, 50-day, 100-day, and 200-day moving averages, it is currently below its 5-day moving average, which may signal a shift in market sentiment. Overall, these factors contribute to the current decline in Checkpoint Trends Ltd's stock price.